Full Breakdown
Economic Impact of Untreated Obstructive Sleep Apnoea in the US and UK
2/25/2026, 10:09:51 AM
Overview of the Economic Burden
Obstructive sleep apnoea (OSA) imposes a significant economic burden on the US and UK, costing approximately £137 billion ($185 billion) annually. This serious health condition, characterized by repeated breathing interruptions during sleep, affects around 1 billion people globally, with an estimated 8 million cases in the UK alone. Alarmingly, up to 85% of those affected remain undiagnosed. A recent study from University College London surveyed over 4,000 adults and found that about 20% reported symptoms indicative of OSA, including excessive daytime sleepiness and breathing pauses during sleep.
Financial Implications of Untreated OSA
The economic analysis indicates that untreated OSA results in substantial productivity losses, estimated at $180 billion in the US and £4.2 billion in the UK each year. These figures primarily account for lost workdays and reduced performance, excluding additional costs related to healthcare and accidents. The study highlights that the average productivity loss per affected worker is approximately $3,727 in the US and £1,840 in the UK, which surpasses the annual cost of standard treatment options like continuous positive airway pressure (CPAP) therapy.
Calls for Workplace Screening
Researchers advocate for the implementation of workplace screening programs, particularly for high-risk occupations such as professional drivers and heavy machinery operators. The rationale is that early identification and treatment of OSA could lead to significant savings in productivity costs. The study's authors emphasize the need for policymakers to develop effective screening strategies and public health campaigns to address this often-overlooked condition.
Criticism and Concerns Regarding Screening
Despite the potential benefits of workplace screening, there are concerns about its implementation. Critics argue that workers may fear job loss or penalties if they disclose their condition or struggle with treatment adherence. Adrian Jones, a national officer at the trade union Unite, expressed the need for protections for professional drivers, stating, “Professional drivers often hide issues of sleep apnoea out of fear of losing their jobs.” Additionally, there are worries about increased medical insurance premiums and privacy concerns associated with screening.
Official Statements on the Need for Action
The study's authors assert, “Given the significant yet often overlooked burden of obstructive sleep apnoea and its economic impact, we urge policymakers to allocate resources towards developing an effective screening strategy.” They also note that successful screening programs would require assurances for workers regarding job security and support.
Future Directions for Screening Trials
To evaluate the effectiveness of workplace screening, researchers suggest conducting trials in occupations with high prevalence rates of OSA, such as professional driving. They propose comparing outcomes like road traffic accidents and absenteeism between screened groups and those receiving standard care. The authors conclude that with advancements in diagnostic technologies and treatment options, the time is ripe for exploring workplace screening initiatives.
Verbatim Quotes
- “Given the significant yet often overlooked burden of [obstructive sleep apnoea] and its economic impact, we urge policymakers to allocate resources towards developing an effective screening strategy and implementing targeted public health campaigns and policies,” — Study Authors
- “Adrian Jones, national officer at Unite, said: “Professional drivers often hide issues of sleep apnoea out of fear of losing their jobs.” — Adrian Jones, National Officer, Unite
This comprehensive analysis underscores the urgent need for action to address the economic and health impacts of obstructive sleep apnoea in the US and UK.
